Four Chinese biopharmaceuticals unveiled early data on respective cancer therapies at the American Society of Hematology (ASH) 2024 meet in San Diego, including Cstone Pharmaceuticals Co. Ltd.’s receptor tyrosine kinase-like orphan receptor 1 (ROR1)-inhibiting antibody-drug conjugate (ADC) in phase I study for lymphomas.

Norwegian University of Science and Technology (NTNU) has synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, macular degeneration, osteoarthritis, osteoporosis, rheumatoid arthritis and Alzheimer’s disease, among others.

Myrobalan Therapeutics Inc. has completed a $24 million series A funding to support development of neurorestorative therapies for CNS diseases.

Researchers at Myrobalan Therapeutics Inc. and Myrobalan Therapeutics Nanjing Co. Ltd. have divulged macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, neurodegeneration, obesity, metabolic diseases, and inflammatory disorders.

Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer.

The identification and evaluation of the activity of a novel, selective, brain-penetrant macrophage...